Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699164 | 0.94 | KMT2A (0.47) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL6701730 | 0.89 | KMT2A (0.48) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL6700031 | 0.88 | KMT2A (0.46) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL6698658 | 0.88 | KMT2A (0.50) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL6700073 | 0.87 | HTT (0.51) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL6701311 | 0.87 | KMT2A (0.45) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL6696335 | 0.86 | ALDH1A1 (0.49) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL5568497 | 0.86 | OPRD1 (0.49) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL29968772 | 0.86 | OPRD1 (0.49) | KMT2AALDH1A1HPGDOPRD1MAOB | |
| SCHEMBL6696311 | 0.86 | HTT (0.52) | KMT2AALDH1A1HPGDOPRD1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-11-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235855-A1 | Phospholipase C inhibitors for use in treating inflammatory disorders | PLA2G4C, PLA2G4B, PLA2G5 | KMT2A 4455/4885ALDH1A1 1583/4885HPGD 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.